数据表1：基于微生物的新型免疫疗法治疗克罗恩病

数据集获取（Figshare）

• 源站标题：Data_Sheet_1_Novel Microbial-Based Immunotherapy Approach for Crohn’'s Disease.pdf
• DOI：10.3389/fmed.2019.00170.s001
• 发布日期：2019-07-19
• 文件数：1 个
• 文件总体积：578.60 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Novel_Microbial-Based_Immunotherapy_Approach_for_Crohn_s_Disease_pdf/8964518

命令行下载

curl -L -o "Data_Sheet_1_Novel Microbial-Based Immunotherapy Approach for Crohn''s Disease.pdf" "https://ndownloader.figshare.com/files/16404191"

文件清单

• Data_Sheet_1_Novel Microbial-Based Immunotherapy Approach for Crohn''s Disease.pdf（578.60 KB）

文件总体积 578.60 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background: Current Crohn’‘s disease (CD) therapies focus on suppressing immune function and come with consequent risk, such as infection and cancer. Notwithstanding, most CD patients still experience disease progression. There is a need for new CD treatment strategies that offer better health outcomes for patients.
Aims: To assess safety, efficacy, and tolerability of a novel microbial-derived immunotherapy, QBECO, that aims to restore rather than suppress immune function in CD.
Methods: A randomized, double-blind, placebo-controlled trial was conducted in 68 patients with moderate-to-severe CD. Primary endpoints: safety and Week 8 clinical improvement. Secondary endpoints: Week 8 clinical response and remission. Week 8 responders continued blinded treatment through Week 16; non-responders received open-label QBECO from Weeks 9–16. Exploratory analyses included immune biomarker and genotype assessments.
Results: QBECO was well-tolerated. Mean reduction in Crohn’'s Disease Activity Index (CDAI) score was −68 for QBECO vs. −31 for placebo at Week 8. Improvement with QBECO continued through Week 16 (-130 CDAI reduction). Week 8 QBECO clinical response, improvement and remission rates were 41.2%, 32.4%, 29.4% vs. 26.5%, 23.5%, 23.5% for placebo. TNFα inhibitor-naïve subjects achieved higher response rates at Week 8 with QBECO (64%) vs. placebo (26%). Specific immune biomarkers were identified that linked to QBECO response.
Conclusion: This proof-of-concept study supports further investigation for the use of QBECO as a novel immunotherapy approach for CD. Biomarker analyses suggests it may be feasible to personalize CD treatment with QBECO. Larger trials are now needed to confirm clinical improvement and the unique biological findings.
Clinical Trial Number: NCT01809275 (https://clinicaltrials.gov/ct2/show/NCT01809275)

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fmed.2019.00170.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Novel_Microbial-Based_Immunotherapy_Approach_for_Crohn_s_Disease_pdf/8964518）。